title: Antiestrogen therapy: uncertainties and risk assessment.
abstract: Tamoxifen is by far the most clinically tested antiestrogenic drug currently used as adjuvant therapy for breast cancer and it continues to provide considerable benefit in this setting. The balance from clinical trials indicates a strong association between the use of tamoxifen and an increase in uterine tumors (three to sixfold). In rats, tamoxifen is a mutagenic, genotoxic hepatocarcinogen. These actions are not related to its estrogen antagonist activity but have been shown to be as a result of metabolic activation of this drug by cytochrome P450 enzymes, resulting in irreversible binding to cellular DNA. The mechanism of endometrial cancer associated with tamoxifen treatment is unclear, although there are two plausible hypotheses: (1), tamoxifen causes damage and mutation to DNA in uterine cells or (2), it promotes the development of endometrial tumors through its estrogen agonist activity. The evidence for a genotoxic effect of tamoxifen in the uterus is highly contentious and, on balance, we have concluded that it is more likely that the estrogenic effects of tamoxifen promote tumor development.
authors.affiliation: MRC Toxicology Unit, Leicester, United Kingdom.
authors.forename: L L
authors.initials: LL
authors.lastname: Smith
authors.forename: I N
authors.initials: IN
authors.lastname: White
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002273:Carcinogens / Q000009:adverse effects; D017024:Chemotherapy, Adjuvant; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D051381:Rats; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology*; D017312:Toremifene / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D002273:Carcinogens; D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene; D003577:Cytochrome P-450 Enzyme System